Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure

Archives of Internal Medicine

Volumn 160, Issue 1, 2000, Pages 53-60

  Gambassi, Giovanni ^a,b   Lapane, Kate L ^b,d   Sgadari, Antonio ^a   Carbonin, Pierugo ^a   Gatsonis, Constantine ^b   Lipsitz, Lewis A ^c   Mor, Vincent ^b   Bernabei, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b BROWN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0034627897     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.1.53     Document Type: Article

References (76)

1. Congestive Heart Failure in the United States: A New Epidemic. Washington, DC: US Dept of Health and Human Services; September 1996:1-6. NHLBI-NIH Data Fact Sheet.
2. American Heart Association. Heart and Stroke Facts: 1996 Statistical Supplement. Dallas, Tex: American Heart Association; 1996:15.
3. Raleigh VS. The demographic time bomb. BMJ. 1997;315:442-443.
4. Hunink MGM, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease, 1980-1990. JAMA. 1997;277:535-542.
5. Coats AJS. Is preventive medicine responsible for the increasing prevalence of heart failure? Lancet. 1998;352(suppl I):39-41.
6. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
7. Centers for Disease Control and Prevention. Changes in mortality from heart failure - United States, 1980-1995. MMWR Morb Mortal Wkly Rep. 1998;47:633-637.
8. Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc. 1997;45: 270-275.
9. Massie BM, Shah NB. Evolving trends in the epidemiology of heart failure: the rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703-712.
10. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157: 99-104.
11. Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997;30:1758-1764.
12. Jaagosild P, Dawson NV, Thomas C, et al. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. Arch Intern Med. 1998;158:1081-1089.
13. Thom TJ, Kannel WB. Congestive heart failure: epidemiology and cost of illness. Dis Manage Health Outcomes. 1997;1:75-83.
14. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. In: Clinical Practice Guideline No. 11. Rockville, Md: Agency for Health Care Policy and Research, 1994:1-22. AHCPR publication 94-0612.
15. Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation & Management of Heart Failure). Circulation. 1995;92:2764-2784.
16. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J. 1997;18:736-753.
17. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335: 490-498.
18. Massie BM. 15 years of heart failure trials: what have we learned? Lancet. 1998; 352(suppl I):29-33.
19. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
20. Eccles M, Freemantle N, Mason J, for the North of England ACE Inhibitor Guideline Development Group. North of England Evidence Based Development Project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ. 1998;316:1369-1375.
21. Adams KF, Gheorghiade M, Uretsky BF, et al. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. Am Heart J. 1998;135:389-397.
22. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
23. Aronow WS. Treatment of congestive heart failure in older persons. J Am Geriatr Soc. 1997;45:1252-1258.
24. American Geriatrics Society Clinical Practice Committee. Heart failure: evaluation and treatment of patients with left ventricular systolic dysfunction .J Am Geriatr Soc. 1998;46:525-529.
25. O'Keeffe ST, Lye M. Heart failure in the elderly: the same syndrome as the clinical trials? In: McMurra JJV, Cleland JGF, eds. Heart Failure in Clinical Practice. London, England: Martin Dunitz; 1996:47-71.
26. Parmley WW. Do we practice geriatric cardiology? J Am Coll Cardiol. 1997;29: 217-218.
27. Lindenfeld JA, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol. 1997;30:1417-1419.
28. Dauterman KW, Massie BM, Gheorghiade M. Heart failure associated with preserved systolic function: a common and costly clinical entity. Am Heart J. 1998; 135(suppl):S310-S319.
29. Krumholz H. Time to focus on the more typical heart-failure patients. Lancet 1998; 352:3-4.
30. Forman DE, Gambassi G. Peculiar complexities in the management of our cardiac patients. Am Coll Cardiol Curr J Rev. March/April 1999:93-94.
31. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867-869.
32. Bernabei R, Gambassi G. The SAGE database: introducing functional outcomes in geriatric pharmaco-epidemiology. J Am Geriatr Soc. 1998;46:250-252.
33. Gambassi G, Landi F, Peng L, et al. Validity of diagnostic and drug data in standardized nursing home assessments: potential for geriatric pharmacoepidemiology. Med Care. 1998;36:167-179.
34. Bernabei R, Gambassi G, Lapane KL, et al. Characteristics of the SAGE database: a new resource tor research on outcomes in long-term care. J Gerontol Med Sci. 1999;54A:M25-M33.
35. Gambassi G, Sgadari A, Lapane K, Landi F, Mor V, Bernabei R. Measuring health outcomes for older people using the SAGE database. Can J Aging. In press.
36. Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. JAMA 1998;279:1877-1882.
37. Landi F, Gambassi G, Lapane K, et al. Comorbidity and drug use in cognitively impaired elderly living in long-term care. Dementia. 1998;9:347-356.
38. Gambassi G, Lapane K, Sgadari A, et al. Prevalence, clinical correlates, and treatment of hypertension in elderly nursing home residents. Arch Intern Med. 1998; 158:2377-2385.
39. World Health Organization. International Classification of Diseases. Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
40. Phillips C, Morris JN, Hawes C, et al. Association of the Resident Assessment Instrument (RAI) with changes in function, cognition, and psychosocial status. J Am Geriatr Soc. 1997;45:986-993.
41. Cleland JGF, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet. 1998;352(suppl I):19-28.
42. Flacker JM, Kiely DK. A practical approach to identifying mortality-related factors in established long-term care residents. J Am Geriatr Soc. 1998;46:1012-1015.
43. Burns RB, McCarthy EP, Moskowitz MA, Ash A, Kane RL, Finch M. Outcomes of older men and women with congestive heart failure. J Am Geriatr Soc. 1997;45: 276-280.
44. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325:293-302.
45. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
46. Fried TR, Mor V. Frailty and hospitalization of long-term stay nursing home residents. J Am Geriatr Soc. 1997;45:265-269.
47. Intrator O, Castle NG, Mor V. Determinants of hospitalization among nursing home residents: results of a national study. Med Care. 1999;37:228-237.
48. Butler J, Hanumanthu S, Chomsky D, Wilson JR. Frequency of low-risk hospital admissions for heart failure. Am J Cardiol. 1998;81:41-44.
49. Narang R, Swedberg K, Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? insights from trials assessing the effects of ACE-inhibitors on exercise capacity. Eur Heart J. 1996;17:120-134.
50. Walsh JT, Charlesworth A, Andrews R, Hawkins M, Cowley AJ. Relation of daily activity levels in patients with chronic heart failure to long-term prognosis. Am J Cardiol. 1997;79:1364-1369.
51. Opasich C, Pasini E, Aquilani R, et al. Skeletal muscle function at low work level as a model for daily activities in patients with chronic heart failure. Eur Heart J. 1997;18:1626-1631.
52. Harrington D, Coats AJS. Skeletal muscle abnormalities and evidence for their role in symptom generation in chronic heart failure. Eur Heart J. 1997;18:1865-1872.
53. Forman DE, Coletta D, Kenny D, et al. Clinical issues related to discontinuing digoxin therapy in elderly nursing home patients. Arch Intern Med. 1991;151: 2194-2198.
54. Pahor M, Guralnik JM, Gambassi G, Bernabei R, Carosella L, Carbonin P. The impact of age on risk of adverse drug reactions to digoxin. J Clin Epidemiol. 1993; 46:1305-1314.
55. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77:832-838.
56. Clark A, Coats AJS. Severity of heart failure and dosages of angiotensin converting enzyme inhibitors. BMJ. 1996;310:973-974.
57. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol. 1997;79:1118-1120.
58. Gattis WA, Larsen RL, Hasselblad V, Bart BA, O'Connor CM. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? Am Heart J. 1998;136:43-48.
59. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med. 1997; 157:2460-2464.
60. Arling ML. Management of heart failure in nursing facility residents and AMDA Heart Failure Guidelines. Nurs Home Med. 1997;5:374-380.
61. Forman DE, Chander RB, Lapane KL, Shah P, Stoukides J. Evaluating the use of angiotensin-converting enzyme inhibitors for elderly nursing home residents with chronic heart failure. J Am Geriatr Soc. 1998;46:1550-1554.
62. Gambassi G, Carbonin PU, Bernabei R. Angiotensin-converting enzyme inhibitors for elderly patients with congestive heart failure. Arch Intern Med. 1998; 158:97-98.
63. Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy. Arch Intern Med. 1996;156:1669-1673.
64. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998;158:26-32.
65. Gambassi G, Forman DE, Lapane KL, et al. Management of heart failure among very old individuals living in long-term care: has the voice of trials spread? Am Heart J. In press.
66. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor under-utilization in heart failure in a community setting. Clin Cardiol. 1998;21:103-108.
67. Rich MW, Brooks K, Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995. Am Heart J. 1998; 135:367-372.
68. Fiskind D, Paris BE, Aronow WS. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1997; 45:809-812.
69. Marine JE, Goldhaber SZ. Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. Chest. 1998;113:115-118.
70. Zuccalà G, Sgadari A, Cocchi A, et al. Effect of age and pathology on left ventricular diastolic dysfunction: the diagnostic yield of doppler echocardiography. J Gerontol. 1995;50:M78-M82.
71. Ghali JK, Kadakia S, Bhatt A, Cooper R, Liao Y. Survival of heart failure patients with preserved versus impaired systolic function: the prognostic implication of blood pressure. Am Heart J. 1992;123:993-997.
72. Taffet GE, Teasdale TA, Bleyer AJ, Kutka NJ, Luchi RJ. Survival of elderly men with congestive heart failure. Age Ageing. 1992;21:49-55.
73. McDermott MM, Feinglas J, Lee P, et al. Preserved left ventricular systolic function versus systolic dysfunction in congestive heart failure: a comparison of clinical characteristics, hospital readmission rates, and survival [abstract]. J. Invest Med. 1996;44:363A.
74. Dauterman K, Rowell RA, Massie B. CHF with preserved systolic function: mortality, readmission rate, and ACE inhibitor effect in a statewide sample of community hospitals [abstract]. Circulation. 1997;96(suppl I):391.
75. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol. 1996;28:1323-1327.
76. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Hear J. 1998;19:481-489.